LTRN (Lantern Pharma) Ending Cash Position: $6.66 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTRN Lantern Pharma Inc LTRN
33 GF Score
Price $2.07
! 2 Warning Signs
View Full Analysis

What is Lantern Pharma Ending Cash Position?

Lantern Pharma LTRN -4.17% 33 Ending Cash Position is $6.66 Mil as of Jun. 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Lantern Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 was $6.66 Mil.

Lantern Pharma's quarterly Ending Cash Position increased from Dec. 2025 ($4.42 Mil) to Mar. 2026 ($4.92 Mil) and increased from Mar. 2026 ($4.92 Mil) to Jun. 2026 ($6.66 Mil).

Lantern Pharma's annual Ending Cash Position declined from Dec. 2023 ($21.94 Mil) to Dec. 2024 ($7.51 Mil) and declined from Dec. 2024 ($7.51 Mil) to Dec. 2025 ($4.42 Mil).

Lantern Pharma Ending Cash Position Related Terms

Lantern Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Lantern Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lantern Pharma Ending Cash Position Chart

Lantern Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 52.52 37.74 21.94 7.51 4.42

Lantern Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.06 8.39 4.42 4.92 6.66
LTRN
33GF Score
Lantern Pharma Inc LTRN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lantern Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Lantern Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.512+-3.089
=4.42

Lantern Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=8.91+-2.25
=6.66

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $6.66 Mil mean?
Lantern Pharma (LTRN) has a Ending Cash Position of $6.66 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lantern Pharma and its competitors.
Is Lantern Pharma's Ending Cash Position too high?
Lantern Pharma's current Ending Cash Position is $6.66 Mil. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's Ending Cash Position compare to ATOS and BYSI?
Lantern Pharma's Ending Cash Position of $6.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current Ending Cash Position is $6.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current Ending Cash Position of $6.66 Mil. The current Ending Cash Position is $6.66 Mil. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current Ending Cash Position is $6.66 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lantern Pharma Business Description

Address 1920 McKinney Avenue, 7th Floor, Dallas, TX, USA, 75201
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score

Get the complete analysis for LTRN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price